ArticlePest management science2026
Discovery of the microtubule-severing protein as the target of antifungal compound heat-stable antifungal factor in Fusarium graminearum and rational design of novel inhibitors.
Article in Pest management science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundThe natural compound heat-stable antifungal factor (HSAF), produced by Lysobacter enzymogenes OH11, exhibits potent inhibitory activity against Fusarium graminearum and effectively controls Fusarium head blight, yet its mechanism remains unclear. Our previous work identified FGSG_09851, a microtubule-severing protein containing a conserved AAA (ATPases associated with diverse cellular activities) domain, binding to HSAF in F. graminearum. Here, we investigated the biological function of FGSG_09851 and explored its potential as an antifungal target.
resultsDeletion of FGSG_09851 led to a marked increase in HSAF resistance in F. graminearum (EC50: 1.602 ± 0.139 vs 0.787 ± 0.156 μg/mL for wild-type), and impaired mycelial growth, conidial germination, conidiation, and virulence. The ΔFGSG_09851 mutant exhibited sparse and disorganized microtubules, consistent with that observed under HSAF treatment. Molecular docking showed that HSAF binds to the active pocket of FGSG_09851 with a binding energy of -7.9 kcal/mol. Using structural features of known AAA+ ATPase inhibitors, we designed three compounds, AH-001, AH-002, and AH-003, which showed antifungal activity. Among them, AH-001 was the most potent, with inhibition rates of 25.5%, 39.5%, and 47.8% against F. graminearum at 120, 150, and 180 μg/mL, respectively. At 180 μg/mL, AH-002 and AH-003 achieved 35.4% and 32.9% inhibition.
conclusionThis study demonstrates that HSAF exerts its antifungal activity against F. graminearum by targeting the microtubule-severing protein FGSG_09851. Guided by this mechanism, we designed and synthesized novel AAA+ ATPase inhibitors with promising antifungal activity. These findings elucidate the mode of action of HSAF and establish microtubule-severing proteins as a promising target class for fungicide development. © 2026 Society of Chemical Industry.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.